Business Description
Elicera Therapeutics AB
ISIN : SE0015382080
Share Class Description:
FRA:8E8: Ordinary SharesCompare
Compare
Traded in other countries / regions
ELIC.Sweden8E8.Germany IPO Date
2021-06-30Description
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.76 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -75.8 | |||||
3-Year EPS without NRI Growth Rate | -76.1 | |||||
3-Year FCF Growth Rate | -144 | |||||
3-Year Book Growth Rate | 1.4 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 65.98 | |||||
9-Day RSI | 65.91 | |||||
14-Day RSI | 62.18 | |||||
6-1 Month Momentum % | -85.02 | |||||
12-1 Month Momentum % | -72.61 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.23 | |||||
Quick Ratio | 4.23 | |||||
Cash Ratio | 4.16 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.2 | |||||
Shareholder Yield % | -44.95 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -80.65 | |||||
ROA % | -52.82 | |||||
ROIC % | -201.73 | |||||
ROCE % | -77.02 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.45 | |||||
Price-to-Tangible-Book | 1.62 | |||||
EV-to-EBIT | -0.47 | |||||
EV-to-Forward-EBIT | -0.09 | |||||
EV-to-EBITDA | -0.47 | |||||
EV-to-Forward-EBITDA | -0.09 | |||||
EV-to-Forward-Revenue | 4.69 | |||||
EV-to-FCF | -0.23 | |||||
Price-to-Net-Current-Asset-Value | 1.62 | |||||
Price-to-Net-Cash | 1.62 | |||||
Earnings Yield (Greenblatt) % | -210.22 | |||||
FCF Yield % | -44.27 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Elicera Therapeutics AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.085 | ||
Beta | -0.81 | ||
Volatility % | 151.45 | ||
14-Day RSI | 62.18 | ||
14-Day ATR (€) | 0.00673 | ||
20-Day SMA (€) | 0.07331 | ||
12-1 Month Momentum % | -72.61 | ||
52-Week Range (€) | 0.047 - 0.508 | ||
Shares Outstanding (Mil) | 35.09 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Elicera Therapeutics AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Elicera Therapeutics AB Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Elicera Therapeutics AB Frequently Asked Questions
What is Elicera Therapeutics AB(FRA:8E8)'s stock price today?
The current price of FRA:8E8 is €0.10. The 52 week high of FRA:8E8 is €0.51 and 52 week low is €0.05.
When is next earnings date of Elicera Therapeutics AB(FRA:8E8)?
The next earnings date of Elicera Therapeutics AB(FRA:8E8) is 2024-08-29.
Does Elicera Therapeutics AB(FRA:8E8) pay dividends? If so, how much?
Elicera Therapeutics AB(FRA:8E8) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |